Recommendations Developed for Cost-Effectiveness Analyses

This article originally appeared here.
Share this content:
Recommendations Developed for Cost-Effectiveness Analyses
Recommendations Developed for Cost-Effectiveness Analyses

THURSDAY, Sept. 15, 2016 (HealthDay News) -- A new set of recommendations has been developed for conduct and reporting of cost-effectiveness analyses, according to a report published in the Sept. 13 issue of the Journal of the American Medical Association.

Gillian D. Sanders, Ph.D., from the Duke Clinical Research Institute in Durham, N.C., and colleagues reviewed the state of the field and developed recommendations to improve the quality of cost-effectiveness analyses. Members of the Second Panel on Cost-Effectiveness in Health and Medicine developed recommendations by consensus over 3.5 years. The recommendations were reviewed by external reviewers and via a public posting process.

The authors recommended the concept of a "reference case" and a set of standard methodological practices that all cost-effectiveness analyses should follow in order to improve quality and comparability. Two reference case analyses should be reported in all cost-effectiveness analyses: one based on a health care sector perspective and one based on a societal perspective. The panel also recommended use of an "impact inventory," which is a structured table that includes consequences intended to clarify the scope and boundaries of the two reference case analyses.

"Major changes include the recommendation to perform analyses from two reference case perspectives and to provide an impact inventory to clarify included consequences," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »